

bluebird bio, Inc.
Form 8-K
December 09, 2014

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): December 8, 2014

bluebird bio, Inc.

(Exact name of registrant as specified in its charter)

DELAWARE 001-35966 13-3680878
(State or other jurisdiction of (Commission (I.R.S. Employer Identification No.)
incorporation) File Number)

150 Second Street Cambridge, MA 02141
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (339) 499-9300

Not Applicable

Edgar Filing: bluebird bio, Inc. - Form 8-K

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Edgar Filing: bluebird bio, Inc. - Form 8-K

Item 8.01 Other Events

On December 8, 2014, bluebird bio, Inc. (“bluebird”) issued a press release announcing clinical data from its Northstar (HGB-204) and HGB-205 clinical trials of its LentiGlobin product candidate presented at the 56th Annual Meeting of the American Society of Hematology in San Francisco, CA on December 8, 2014. The full text of bluebird’s press release regarding the announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press release issued by bluebird bio, Inc. on December 8, 2014.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

bluebird bio, Inc.

Date: December 8, 2014 By: /s/ Jason F. Cole
Jason Cole
Senior Vice President, General Counsel

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release issued by bluebird bio, Inc. on December 8, 2014.